This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic Gets FDA Nod for Guardian CGM's Android Version
by Zacks Equity Research
Medtronic (MDT) expands reach to diabetic patients by introducing the Guardian Connect CGM system's Android version post its FDA clearance.
Here's Why You Should Add Surmodics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high in Surmodics (SRDX) stock, thanks to solid prospects.
Here's Why You Should Hold on to Edwards Lifesciences for Now
by Zacks Equity Research
Investors continue to be optimistic about Edwards Lifesciences (EW) on robust demand for products and a promising surgical structural heart business.
Medtronic Launches Kyphon Cannula for Balloon Kyphoplasty
by Zacks Equity Research
Medtronic's (MDT) new cannula will complement its entire portfolio of balloon kyphoplasty products, including Kyphon Xpander II Inflatable Bone Tamps.
Here's Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN) on its focus on partnerships and robust demand for its products.
ResMed (RMD) Launches Digital Tool for Remote Mask Selection
by Zacks Equity Research
Based on a brief questionnaire remotely filled by the patient, the MaskSelector tool recommends the best suitable ResMed (RMD) mask for patients.
Neogen (NEOG) Introduces Upgraded Igenity Beef Genomic Profile
by Zacks Equity Research
Neogen (NEOG) looks to provide better technology and information to commercial beef producers to take better decisions for their profitability.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) on its focus on digital health technology and robust demand for its critical care products.
Organigram (OGI) Catches Eye: Stock Jumps 11.7%
by Zacks Equity Research
Organigram (OGI) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.
Myriad's (MYGN) EndoPredict Grows Amid Coronavirus Mayhem
by Zacks Equity Research
Within Molecular Diagnostics, Myriad Genetics (MYGN) registers strong sales for EndoPredict, myChoice CDx and BRACAnalysis CDx.
Hologic's Second Molecular Test Gets EUA to Detect Coronavirus
by Zacks Equity Research
Hologic (HOLX) expects to boost testing capacity by combining its manufacturing ability for the latest EUA of test with its largest installed base of high-throughput molecular instruments.
Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) registered growth in one of its core units, Invitro Diagnostics, in Q2.
SurModics (SRDX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 180.00% and 1.57%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Inogen (INGN) Stock for Now
by Zacks Equity Research
Investor confidence is high on Inogen (INGN) stock, thanks to solid prospects.
AMN Healthcare Inks Deal to Address Healthcare System Needs
by Zacks Equity Research
This partnership is expected to boost AMN Healthcare's (AMN) Other Workforce Solutions segment.
Earnings Preview: SurModics (SRDX) Q2 Earnings Expected to Decline
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacific Biosciences' Sequel II Gets Acquired by inqaba biotec
by Zacks Equity Research
Pacific Biosciences' (PACB) new development is likely to boost the company's flagship platform, the Sequel system.
Here's Why You Should Retain Accuray in Your Portfolio
by Sriparna Ghosal
Investor confidence remains high in Accuray (ARAY) stock, thanks to solid prospects.
Here's Why You Should Retain OPKO Health in Your Portfolio
by Zacks Equity Research
Investor confidence remains high in OPKO Health's (OPK) stock, thanks to solid prospects.
Amedisys Gains on Expanding Hospice Arm, Favorable Demography
by Zacks Equity Research
Amedisys' (AMED) recent acquisitions in the Hospice arm aid the company's growth.
Intersect Posts Preliminary Q1 Results, Withdraws '20 View
by Zacks Equity Research
Intersect (XENT) expects the impact of the coronavirus pandemic to substantially dampen revenues in the second quarter as well.
Here's Why You Should Add ResMed (RMD) in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) on its focus on digital health technology and combatting the coronavirus outbreak.
Here's Why You Should Retain Allscripts in Your Portfolio Now
by Zacks Equity Research
Investor confidence remains high in Allscripts' (MDRX) stock, thanks to solid prospects.
PRA Health Unit to Offer Free Access to Metys COVID-19 Module
by Zacks Equity Research
PRA Health's (PRAH) new module is likely to boost Data Solutions segment.
Bio-Rad Rides on International Expansion Amid Cost Concerns
by Zacks Equity Research
Each of Bio-Rad's (BIO) key segments registers solid growth across three major geographies of America, Europe and Asia.